Amyris Biotechnologies, which uses genetically modified yeast to make products for specialty chemical/fuel markets, raised $85 million by offering 5.3 million shares at $16, below the range of $18-$20. Amyris Biotechnologies is expected to open for trading on Tuesday on the NASDAQ under the symbol AMRS. Morgan Stanley, Goldman, Sachs & Co. and J.P. Morgan acted as lead managers on the deal.
